Activity of Gemifloxacin against Quinolone-Resistant Streptococcus pneumoniae Strains In Vitro and in a Mouse Pneumonia Model
Open Access
- 1 March 2005
- journal article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 49 (3) , 1046-1054
Abstract
Gemifloxacin is a novel fluoronaphthyridone quinolone with enhanced in vitro activity against Streptococcus pneumoniae . We investigated the activities of gemifloxacin and trovafloxacin, their abilities to select for resistance in vitro and in vivo, and their efficacies in a mouse model of acute pneumonia. Immunocompetent Swiss mice were infected with 10 5 CFU of a virulent, encapsulated S. pneumoniae strain, P-4241, or its isogenic parC , gyrA , parC gyrA , and efflux mutant derivatives (serotype 3); and leukopenic mice were infected with 10 7 CFU of two poorly virulent clinical strains (serotype 11A) carrying either a parE mutation or a parC , gyrA , and parE triple mutation. The drugs were administered six times every 12 h, starting at either 3 or 18 h postinfection. In vitro, gemifloxacin was the most potent agent against strains with and without acquired resistance to fluoroquinolones. While control mice died within 6 days, gemifloxacin at doses of 25 and 50 mg/kg of body weight was highly effective (survival rates, 90 to 100%) against the wild-type strain and against mutants harboring a single mutation, corresponding to area under the time-versus-serum concentration curve at 24 h (AUC 24 )/MIC ratios of 56.5 to 113, and provided a 40% survival rate against a mutant with a double mutation ( parC and gyrA ). A total AUC 24 /MIC ratio of 28.5 was associated with poor efficacy and the emergence of resistant mutants. Trovafloxacin was as effective as gemifloxacin against mutants with single mutations but did not provide any protection against the mutant with double mutations, despite treatment with a high dose of 200 mg/kg. Gemifloxacin preferentially selected for parC mutants both in vitro and in vivo.Keywords
This publication has 38 references indexed in Scilit:
- Activities of Garenoxacin against Quinolone-Resistant Streptococcus pneumoniae Strains In Vitro and in a Mouse Pneumonia ModelAntimicrobial Agents and Chemotherapy, 2004
- Gatifloxacin, Gemifloxacin, and Moxifloxacin: The Role of 3 Newer FluoroquinolonesClinical Infectious Diseases, 2003
- Mutant Prevention Concentration of Gemifloxacin for Clinical Isolates of Streptococcus pneumoniaeAntimicrobial Agents and Chemotherapy, 2003
- In Vitro Development of Resistance to Six Quinolones in Streptococcus pneumoniae, Streptococcus pyogenes , and Staphylococcus aureusAntimicrobial Agents and Chemotherapy, 2001
- Practice Guidelines for the Management of Community-Acquired Pneumonia in AdultsClinical Infectious Diseases, 2000
- Comparative in vitro activity and post-antibiotic effect of gemifloxacin against Legionella spp.Journal of Antimicrobial Chemotherapy, 2000
- Comparative potency of gemifloxacin, new quinolones, macrolides, tetracycline and clindamycin against Mycoplasma spp.Journal of Antimicrobial Chemotherapy, 2000
- Multiple pathogens in adult patients admitted with community-acquired pneumonia: a one year prospective study of 346 consecutive patients.Thorax, 1996
- Emerging Resistance to Antimicrobial Agents in Gram-Positive BacteriaDrugs, 1996
- Antimicrobial Resistance in Streptococcus pneumoniae: An OverviewClinical Infectious Diseases, 1992